Serum Institute to begin Sputnik V production in September

India is the leading production hub for production of Sputnik vaccine, it added.

"RDIF is delighted to cooperate with Serum Institute of India, the world''s largest vaccine manufacturer. This strategic partnership is a major step to substantially increase our production capabilities demonstrating a perfect example of joining forces and expertise to save lives both in India and around the world," RDIF CEO Kirill Dmitriev said.

With technology transfer underway, "we expect the first batches of the vaccine to be produced jointly with SII in coming months," he added.

As of now Sputnik V vaccine has been registered in 67 countries globally, RDIF said.

"We hope to make millions of doses in the coming months with trial batches starting in the month of September," Serum Institute of India CEO Adar Poonawalla said.

With high efficacy and a good safety profile, it is critical that the Sputnik vaccine is accessible in full measure for people across India and the world, he added.

India is the leading production hub for production of Sputnik vaccine.

Efficacy of Sputnik V is 97.6 per cent based on the analysis of data on the coronavirus infection rate among those in Russia vaccinated with both components of Sputnik V from December 5, 2020, to March 31, 2021, RDIF said.